Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of shareholders of Chemed Corporation (“Chemed” or the “Company”) (NYSE:CHE) concerning possible breaches of fiduciary duties by the Company or its fiduciaries. Chemed, through its subsidiaries, operates in the healthcare and repair and maintenance fields in the United States. The Company’s Vitas segment offers hospice and palliative patient-care services through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Please contact us at (212) 682-5340, toll-free at (888) 773-9224, or at firstname.lastname@example.org to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
The investigation is related to allegations that Chemed billed Medicare for unnecessary and fraudulent treatments – including billing for hospice care for patients who were not terminally ill – and whether the Company’s board of directors breached their fiduciary duties or allowed Chemed to engage in potential violations of the federal False Claims Act. In May 2013, the United States Department of Justice filed a lawsuit under the False Claims Act against Chemed and its affiliates, alleging that the Company systematically defrauded Medicare.
If you purchased Chemed shares and still hold those shares, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV